Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Dec 22;33(3):632–638. doi: 10.2337/dc09-0305

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2010 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

A–F: Glucose, insulin, C-peptide, C-peptide–to–glucose ratio, GLP-1, and glucagon, respectively, during the OGTT in Ab⁻ CDx-type 2 diabetes (▵) versus Ab⁺ CDx-type 2 diabetic patients (▴) versus obese control subjects (●). G–L: Area under the curve (AUC) for glucose, insulin, C-peptide, C-peptide–to–glucose ratio, GLP-1, and glucagon relative to glucose, respectively, during the OGTT in Ab⁻ CDx-type 2 diabetes (□) versus Ab⁺ CDx-type 2 diabetes (■) versus obese control subjects (). Data adjusted for BMI. *P ≤ 0.001 for Ab⁺ vs. Ab⁻ post hoc Bonferroni correction.

Inline graphic — A–F: Glucose, insulin, C-peptide, C-peptide–to–glucose ratio, GLP-1, and glucagon, respectively, during the OGTT in Ab⁻ CDx-type 2 diabetes (▵) versus Ab⁺ CDx-type 2 diabetic patients (▴) versus obese control subjects (●). G–L: Area under the curve (AUC) for glucose, insulin, C-peptide, C-peptide–to–glucose ratio, GLP-1, and glucagon relative to glucose, respectively, during the OGTT in Ab⁻ CDx-type 2 diabetes (□) versus Ab⁺ CDx-type 2 diabetes (■) versus obese control subjects (). Data adjusted for BMI. *P ≤ 0.001 for Ab⁺ vs. Ab⁻ post hoc Bonferroni correction.